Table 1. Clinical characteristics of HCC patients in the training and validation cohorts.
| Variable | Training Set, n = 168 | Validation Set, n = 183 | |||
|---|---|---|---|---|---|
| PVTT | No-PVTT | P value | P’ value | ||
| No. of patients | 47 | 121 | 183 | ||
| Age, years, Mean ± SD | 53.9 ± 10.9 | 52.8 ± 12.5 | 0.396 | 53.7 ± 10.5 | 0.245 |
| Gender | 0.829 | 0.669 | |||
| Male | 41 | 104 | 155 | ||
| Female | 6 | 17 | 28 | ||
| Hepatitis B, n (%) | 38 (81) | 103 (85) | 0.498 | 156 (85) | 0.733 |
| Child-Pugh | 0.759 | 0.665 | |||
| A | 42 | 110 | 163 | ||
| B | 5 | 11 | 20 | ||
| AFP | 0.204 | 0.861 | |||
| < 200ng/ml | 17 | 58 | 80 | ||
| ≥ 200ng/ml | 29 | 64 | 103 | ||
| Tumor size | 0.000 | 0.803 | |||
| ≥ 5cm | 36 | 0 | 41 | ||
| < 5cm | 11 | 121 | 142 | ||
| TBIL (umol/L), mean ± SD | 19.3 ± 17.8 | 15.0 ± 5.9 | 0.112 | 18.2 ± 12.1 | 0.166 |
| DBIL (umol/L), mean ± SD | 9.0 ± 11.2 | 6.4 ± 6.5 | 0.137 | 7.0 ± 7.2 | 0.735 |
| ALT (IU/L), mean ± SD | 49 ± 32.3 | 53.4 ± 35.6 | 0.466 | 46.8 ± 49.5 | 0.790 |
| AST (IU/L), mean ± SD | 75.1 ± 48.5 | 68.0 ± 52.1 | 0.422 | 61.1 ± 64.1 | 0.947 |
| GGT (IU/L), mean ± SD | 217.3 ± 164.5 | 196.7 ± 220.7 | 0.564 | 170.6 ± 191.7 | 0.792 |
| LDH (IU/L), mean ± SD | 273.2 ± 163.1 | 236.6 ± 141.4 | 0.152 | 237.9 ± 144.6 | 0.685 |
| ALP (IU/L), mean ± SD | 214.1 ± 287.5 | 131.4 ± 70.5 | 0.057 | 144.3 ± 110.4 | 0.996 |
| ALB (IU/L), mean ± SD | 38.9 ± 6.4 | 39.7 ± 4.8 | 0.391 | 39.1 ± 4.7 | 0.686 |
AFP, alpha fetoprotein; TBIL, total bilirubin; D-TBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, glutamyl transferase; LDH, lactic dehydrogenase; ALP, alkaline phosphatase; ALB, albumin.